直接作用抗病毒药物与司库奇尤单抗联合使用时的疗效和安全性。
Efficacy and safety of direct-acting antiviral agents when combined with secukinumab.
作者信息
Martinez-Santana Virginia, Rodriguez-Murphy Esther, Smithson Alex, Miserachs-Aranda Nuria, Del Río-Gil Ruben, Torre-Lloverás Inmaculada
机构信息
Pharmacy, Fundació Hospital de l'Esperit Sant, Santa Coloma de Gramenet, Barcelona, Spain.
Infectious Diseases Unit, Fundació Hospital de l'Esperit Sant, Santa Coloma de Gramenet, Barcelona, Spain.
出版信息
Eur J Hosp Pharm. 2018 Jan;25(1):53-56. doi: 10.1136/ejhpharm-2017-001212. Epub 2017 May 20.
BACKGROUND
The interference in the immune response induced by biological disease-modifying antirheumatic drugs (bDMARDs) increases the risk of reactivation of infections. Treatment of patients with chronic hepatitis C virus (HCV) infection and psoriasis is complex. The efficacy and safety of the new direct-acting antiviral agents (DAA) when combined with bDMARDs remain unknown.
CASE REPORT
We present a case of a 44-year-old Caucasian man affected with psoriasis and HCV infection. Throughout the course of the psoriatic disease, this patient received several lines of treatment, including secukinumab, a new type of bDMARD. At the time of commencing secukinumab, new DAA agents (ledipasvir/sofosbuvir) were also initiated. At week 12 post-treatment, hepatitis C viral load was undetectable and the patient remained in remission of psoriasis.
CONCLUSION
This case report suggests that secukinumab is a therapeutic option in patients with psoriasis, particularly in those cases with HCV infection where treatment with DAA agents is warranted.
背景
生物性改善病情抗风湿药物（bDMARDs）对免疫反应的干扰会增加感染再激活的风险。慢性丙型肝炎病毒（HCV）感染患者合并银屑病的治疗较为复杂。新型直接抗病毒药物（DAA）与bDMARDs联合使用时的疗效和安全性尚不清楚。
病例报告
我们报告一例44岁患有银屑病和HCV感染的白种男性病例。在银屑病病程中，该患者接受了多种治疗方案，包括新型bDMARD司库奇尤单抗。在开始使用司库奇尤单抗时，同时启动了新型DAA药物（来迪派韦/索磷布韦）。治疗后第12周，丙型肝炎病毒载量检测不到，且患者的银屑病仍处于缓解期。
结论
本病例报告表明，司库奇尤单抗是银屑病患者的一种治疗选择，尤其是在那些有必要使用DAA药物治疗的HCV感染病例中。
Zotero 插件